



REGULAR ARTICLE

Synthesis and antibacterial activity of benzothiazole and benzoxazole-appended substituted 1,2,3-triazoles

C P KAUSHIK* and MANISHA CHAHAL

Department of Chemistry, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, India
E-mail: kaushikcp@gmail.com

MS received 10 June 2020; revised 9 August 2020; accepted 12 August 2020; published online 24 October 2020

Abstract. A series of benzothiazole and benzoxazole linked 1,4-disubstituted 1,2,3-triazoles was synthesized through copper(I) catalyzed azide-alkyne cycloaddition reaction. FTIR, ^1H , ^{13}C -NMR and HRMS techniques were used to examine the structure of synthesized derivatives. Further, these triazole derivatives were screened for *in vitro* antibacterial activities against two Gram-positive bacteria *S. aureus*, *B. subtilis*; two Gram-negative bacteria *E. coli* and *K. pneumoniae* by serial dilution technique, reflecting moderate to good activity. Compound **7s** exhibited promising antibacterial activity among all the synthesized triazoles.

Keywords. 1,4-disubstituted 1,2,3-triazoles; antibacterial activity; benzothiazole; benzoxazole.

Abbreviations

MIC Minimum Inhibitory Concentration
MTCC Microbial Type Culture Concentration
NCDC National Collection of Dairy Culture

1. Introduction

Heterocycles are an important class that is pervasive in vital bioactive molecules. Among various heterocycles, benzothiazole and benzoxazole compounds have been explored in past and are still in practice for a variety of therapeutic applications which makes this scaffold an interesting moiety for designing new broad-spectrum pharmacophore. Benzothiazole and benzoxazole and their derivatives have depicted various admirable biological properties in form of antioxidant,¹ anticancer,^{2,3} anti-inflammatory,⁴ analgesic⁵ and acetylcholinesterase inhibitory⁶ agents. Some of the important marketed drugs having benzothiazole and benzoxazole ring in their structures are Riluzole, Pramipexole, flunoxaprofen, benoxaprofen (Figures 1, 2, 3, 4), etc.

Molecules having triazole nucleus leads to diversified applications in medicine, agriculture, etc. The triazole derivatives have been found to possess immense biological importance like antitubercular,⁷ anti-cancer,^{8–13} antiparasitic,¹⁴ antimicrobial,^{15–22} antileishmanial,²³ antioxidant,^{24,25} anti-inflammatory,^{26–29} and anti-malarial,³⁰ α -glycosidase inhibitory,³¹ antiviral,³² antidepressant,³³ acetylcholinesterase inhibitory^{34,35} activities have been identified. Triazole nucleus enjoys its importance as the core structure of blockbuster drugs such as fluconazole, Rufinamide, Cefatrizine, etc. In recent years, the chemistry of triazoles and its heterocyclic derivatives led to the development of lead compounds in medicinal chemistry. Owing to this, here click reaction has been used for the formation (synthesis) of 1,4-disubstituted 1,2,3-triazoles from azides and terminal alkynes. “Click” chemistry approach has been formulated to insert a link between triazole nucleus and benzothiazole and benzoxazole moiety with a thought to explore the synergic effect of these two scaffolds. The synthesized 1,2,3-triazoles containing benzothiazole and benzoxazole have also been explored for antibacterial activity against *Staphylococcus aureus*, *Bacillus subtilis*, *Klebsiella pneumoniae* and *Escherichia coli*.

*For correspondence

Electronic supplementary material: The online version of this article (<https://doi.org/10.1007/s12039-020-01844-8>) contains supplementary material, which is available to authorized users.




Figure 1. Riluzole.




Figure 2. Pramipexole.




Figure 3. Flunoxaprofen.




Figure 4. Benoxaprofen.

2. Experimental

2.1 Chemistry

The starting materials were purchased from Sigma-Aldrich, Alfa-Aesar, Hi-Media and used without any further purification. Melting points (°C) were determined by an open capillaries method and uncorrected. To monitor the progress of the reaction and to check the purity of compounds, thin-layer chromatography (TLC) was performed using silica gel plates (SIL G/UV254, ALUGRAM). The IR spectra were taken on SHIMAZDU IR AFFINITY-I FTIR spectrometer using potassium bromide (KBr) powder and values are given in cm^{-1} . Nuclear magnetic resonance (NMR) spectra were recorded on BRUKER AVANCE II apparatus operating at 400 MHz (^1H) and 100 MHz (^{13}C), in DMSO, and chemical shifts (δ) are given in parts per million downfield from the internal standard trimethylsilane (TMS). Coupling constant (J) values were observed in Hertz (Hz). HRMS were observed on Bruker micro TOF Q-II spectrometer.

General procedure for the synthesis of terminal Alkyne^{36,37} (3a-3b): The 2-(prop-2-yn-1-ylthio)benzo[d]oxazole (**3a**)/2-(prop-2-yn-1-ylthio)benzo[d]thiazole (**3b**) were synthesized by dropwise addition of propargyl bromide (**2**) (1.0 mmol) to the solution of 2-mercaptobenzoxazole (**1a**)/2-mercaptobenzothiazole (**1b**) (1.0 mmol) in *N,N*-dimethylformamide in presence of potassium carbonate as base at 0–10 °C for 3 h. After the completion of the reaction, the cooled reaction mixture was poured in ice-cold

water and the precipitated products were filtered to get the desired alkynes (**3a-3b**).

General procedure for the synthesis of 4-(bromomethyl)-*N*-arylbenzamide derivatives (6a-6j): The aromatic amines (**5a-5j**) (1.0 mmol) were reacted with 4-(bromomethyl)benzoylbromide (**4**) (1.0 mmol) in dichloromethane and potassium carbonate as a base at 0–10 °C for 2–3 h. After the completion of the reaction as indicated by TLC, the product was extracted with dichloromethane and the organic layer was dried with anhydrous sodium sulphate and concentrated under reduced pressure to obtain 4-(bromomethyl)-*N*-arylbenzamide derivatives (**6a-6j**) with 80–90% yield.

General procedure for the synthesis of 1,4-disubstituted 1,2,3-triazole derivatives (7a-7t): The targeted 1,4-disubstituted 1,2,3-triazoles with amide and thioether functionality were synthesized by the reaction of 2-(prop-2-yn-1-ylthio)benzo[d]oxazole (**3a**)/2-(prop-2-yn-1-ylthio)benzo[d]thiazole (**3b**) (1.0 mmol), 4-(bromomethyl)-*N*-arylbenzamide derivatives (**6a-6j**) (1.0 mmol) and sodium azide using dimethylformamide:water as a solvent in the presence of the catalytic amount of copper sulphate pentahydrate and sodium ascorbate with stirring for 6–10 h at ambient temperature. After the completion of the reaction, the reaction mixture was quenched with ice-cold water and ammonia solution, the precipitates were filtered and recrystallized from ethyl acetate to yield the pure 1,4-disubstituted 1,2,3-triazoles (**7a-7t**).

2.2 Characterization of benzothiazole and benzoxazole linked 1,4-disubstituted 1,2,3-triazoles

2.2a 4-((4-((benzo[d]oxazol-2-ylthio)methyl)-1*H*-1,2,3-triazol-1-yl)methyl)-*N*-phenylbenzamide

(**7a**): Appearance: Brown solid; yield: 79%; M.p.: 152–156 °C; FTIR (KBr): ν_{max} = 3336 (N–H str.), 3143 (C–H str., triazole ring), 2881 (C–H str., aliphatic), 1653 (C=O sym. str., amide), 1500, 1442 (C=C str., aromatic ring), 692 (C–S str.) cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6) δ 10.23 (s, 1H, -CONH), 8.24 (s, 1H, C–H triazole), 8.02 (d, J = 8.0 Hz, 1H, ArH), 7.91 (d, J = 8.0 Hz, 2H, ArH), 7.76 (d, J = 8.0 Hz, 1H, ArH), 7.48 (t, J = 8.0, 1H, ArH), 7.41–7.08 (m, 7H, ArH), 5.68 (s, 2H, -NCH₂), 4.71 (s, 2H, -SCH₂); ^{13}C NMR (100 MHz, DMSO) δ 165.56 (C=O), 151.81, 143.14 (C₄ triazole), 141.71, 139.76, 139.53, 135.25, 129.06, 128.55, 128.25, 125.12, 124.85, 124.62 (C₅ triazole), 124.17, 120.79, 118.85, 110.73, 52.90 (-SCH₂), 26.95 (-NCH₂); HRMS (m/z) calculated for C₂₄H₁₉N₅O₂S [M+H]⁺: 442.1293. Found: 442.1318.

2.2b 4-((4-((benzo[d]oxazol-2-ylthio)methyl)-1*H*-1,2,3-triazol-1-yl)methyl)-*N*-(*o*-tolyl)benzamide

(**7b**): Appearance: White solid; yield: 81%; M.p.: 152–156 °C; FTIR (KBr): ν_{max} = 3257 (N–H str.), 3124

(C–H str., triazole ring), 2983 (C–H str., aliphatic), 1643 (C=O sym. str., amide), 1500, 1452 (C=C str., aromatic ring), cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6) δ 9.83 (s, 1H, -CONH), 8.22 (s, 1H, C-H triazole), 7.88 (d, $J = 8.0$ Hz, 2H), 7.625 (d, $J = 4.0$ Hz, 2H, ArH), 7.36 (d, $J = 8.0$ Hz, 2H, ArH), 7.32–7.26 (m, 3H, ArH), 7.23 (d, $J = 8.0$ Hz, 1H, ArH), 7.19–7.12 (m, 2H, ArH), 5.63 (s, 2H, -NCH₂), 4.65 (s, 2H, -SCH₂), 2.17 (s, 3H, -CH₃). ^{13}C NMR (100 MHz, DMSO) δ 165.36 (C=O), 151.85, 143.21 (C₄ triazole), 141.75, 130.85, 130.85, 128.60, 128.39, 127.07, 126.55, 125.20, 124.93, 124.73 (C₅ triazole), 118.91, 110.82, 52.93 (-SCH₂), 26.96 (-NCH₂), 18.40; HRMS (m/z) calculated for C₂₅H₂₁N₅O₂S [M+H]⁺: 456. 1450. Found: 456.1493.

2.2c 4-((4-((benzo[d]oxazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(*m*-tolyl)benzamide

(**7c**): Appearance: White solid; yield: 85%; M.p.: 152–156 °C; FTIR (KBr): ν_{max} = 3346 (N–H str.), 3115 (C–H str., triazole ring), 2918 (C–H str., aliphatic), 1653 (C=O sym. str., amide), 1527, 1440 (C=C str., aromatic ring), cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6) δ 10.14 (s, 1H, -CONH), 8.22 (s, 1H, C-H triazole), 7.85 (d, $J = 8.0$ Hz, 2H, ArH), 7.64–7.58 (m, 3H, ArH), 7.35 (d, $J = 8.0$ Hz, 2H, ArH), 7.30 (t, $J = 8.0$ Hz, 2H, ArH), 7.20 (s, 1H, ArH), 7.11 (d, $J = 8.0$ Hz, 2H), 5.63 (s, 2H, -NCH₂), 4.65 (s, 2H, -SCH₂), 2.23 (s, 3H, -CH₃). ^{13}C NMR (100 MHz, DMSO) δ 166.22 (C=O), 165.42, 153.09, 143.30 (C₄ triazole), 139.79, 137.06, 135.24, 133.19, 129.54, 128.56, 128.28, 126.92, 125.11, 124.80 (C₅ triazole), 122.38, 121.80, 120.84, 52.91 (-SCH₂), 27.94 (-NCH₂), 21.03; HRMS (m/z) calculated for C₂₅H₂₁N₅O₂S [M+H]⁺: 456. 1450. Found: 456.1506.

2.2d 4-((4-((benzo[d]oxazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(*p*-tolyl)benzamide

(**7d**): Appearance: White solid; yield: 82%; M.p.: 152–156 °C; FTIR (KBr): ν_{max} = 3361 (N–H str.), 3109 (C–H str., triazole ring), 2951 (C–H str., aliphatic), 1643 (C=O sym. str., amide), 1517, 1423 (C=C str., aromatic ring), cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6) δ 10.11 (s, 1H, -CONH), 8.22 (s, 1H, C-H triazole), 7.84 (d, $J = 8.0$ Hz, 2H, ArH), 7.62 (d, $J = 8.0$ Hz, 2H), 7.55 (s, 1H, ArH), 7.50 (d, $J = 8.0$ Hz, 1H, ArH), 7.35 (d, $J = 8.0$ Hz, 2H, ArH), 7.30 (m, 2H, ArH), 7.18 (m, 1H, ArH), 6.88 (d, $J = 8.0$ Hz, 1H, ArH), 5.63 (s, 2H, -NCH₂), 4.65 (s, 2H, -SCH₂), 2.26 (s, 3H, -CH₃); ^{13}C NMR (100 MHz, DMSO) δ 165.66 (C=O), 151.92, 143.23 (C₄ triazole), 141.74, 139.83, 139.50, 138.30, 135.31, 129.00, 128.60, 128.32, 125.21, 124.93, 124.74 (C₅ triazole), 121.35, 118.91, 118.00, 110.82, 52.92 (-SCH₂), 26.96 (-NCH₂), 21.74; HRMS (m/z) calculated for C₂₅H₂₁N₅O₂S [M+H]⁺: 456. 1450. Found: 456.1503.

2.2e 4-((4-((benzo[d]oxazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(4-methoxyphenyl)benzamide (**7e**):

Appearance: White solid; yield: 83%; M.p.: 152–156 °C; FTIR (KBr): ν_{max} = 3311 (N–H str.), 3115 (C–H str., triazole ring), 2954 (C–H

str., aliphatic), 1645 (C=O sym. str., amide), 1508, 1409 (C=C str., aromatic ring), cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6) δ 10.22 (s, 1H, -CONH), 8.28 (s, 1H, C-H triazole), 7.93 (s, 1H, ArH), 7.67–7.42 (m, 10H, ArH), 6.92 (s, 1H, ArH), 5.67 (s, 2H, -NCH₂), 4.67 (s, 2H, -SCH₂), 3.24 (s, 3H, -OCH₃); ^{13}C NMR (100 MHz, DMSO) δ 165.14 (C=O), 156.03, 143.13 (C₄ triazole), 141.79, 139.61, 135.16, 132.62, 128.51, 128.20, 125.13, 124.86, 124.72 (C₅ triazole), 122.47, 118.84, 114.16, 110.75, 55.64, 52.87 (-SCH₂), 26.92 (-NCH₂); HRMS (m/z) calculated for C₂₅H₂₁N₅O₃S [M+H]⁺: 472. 1399. Found: 472.1446.

2.2f 4-((4-((benzo[d]oxazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(4-nitrophenyl)benzamide

(**7f**): Appearance: White solid; yield: 78%; M.p.: 152–156 °C; FTIR (KBr): ν_{max} = 3354 (N–H str.), 3107 (C–H str., triazole ring), 2942 (C–H str., aliphatic), 1658 (C=O sym. str., amide), 1504, 1406 (C=C str., aromatic ring), cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6) δ 10.77 (s, 1H, -CONH), 8.29 (s, 1H, C-H triazole), 8.26 (m, 2H, ArH), 8.045 (d, $J = 12.0$ Hz, 2H, ArH), 7.93 (d, $J = 8.0$ Hz, 2H, ArH), 7.69–7.62 (m, 2H, ArH), 7.43 (d, $J = 8.0$ Hz, 2H, ArH), 7.39–7.30 (m, 2H, ArH), 5.69 (s, 2H, -NCH₂), 4.69 (s, 2H, -SCH₂). ^{13}C NMR (100 MHz, DMSO) δ 166.31 (C=O), 151.81, 145.84, 143.00 (C₄ triazole), 141.71, 140.45, 134.48, 128.83, 128.36, 125.26, 125.12, 124.85, 124.66 (C₅ triazole), 120.31, 118.85, 110.73, 52.87 (-SCH₂), 26.95 (-NCH₂); HRMS (m/z) calculated for C₂₄H₁₈N₆O₂S [M+H]⁺: 487. 1144. Found: 487.1177.

2.2g 4-((4-((benzo[d]oxazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(4-fluorophenyl)benzamide (**7g**):

Appearance: Brown solid; yield: 81%; M.p.: 152–156 °C; FTIR (KBr): ν_{max} = 3365 (N–H str.), 3128 (C–H str., triazole ring), 3078 (C–H str., aliphatic), 1660 (C=O sym. str., amide), 1508, 1450 (C=C str., aromatic ring), 685 (C–S str.) cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6) δ 10.26 (s, 1H, -CONH), 8.25 (s, 1H, C-H triazole), 7.90 (d, $J = 8.0$ Hz, 2H, ArH), 7.77 (dd, $J = 8.0, 4.0$ Hz, 2H, ArH), 7.67–7.65 (m, 2H, ArH), 7.40 (d, $J = 8.0$ Hz, 2H, ArH), 7.36–7.33 (m, 2H, ArH), 7.22–7.18 (m, 2H, ArH), 5.68 (s, 2H, -NCH₂), 4.69 (s, 2H, -SCH₂); ^{13}C NMR (100 MHz, DMSO) δ 165.48 (C=O), 163.96, 151.82, 143.15 (C₄ triazole), 141.72, 139.84, 135.92, 135.07, 128.53, 128.28, 125.13, 124.86, 124.63 (C₅ triazole), 122.66, 122.59, 118.86, 115.76, 115.54, 110.73, 52.89 (-SCH₂), 26.96 (-NCH₂); HRMS (m/z) calculated for C₂₄H₁₈FN₅O₂S [M+H]⁺: 460. 1199. Found: 460.1254.

2.2h 4-((4-((benzo[d]oxazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(4-chlorophenyl)benzamide (**7h**):

Appearance: White solid; yield: 77%; M.p.: 152–156 °C; FTIR (KBr): ν_{max} = 3298 (N–H str.), 3132 (C–H str., triazole ring), 2848 (C–H str., aliphatic), 1654 (C=O sym. str., amide), 1498, 1454 (C=C str., aromatic ring), cm^{-1} ; ^1H NMR (400 MHz,

DMSO- d_6) δ 10.40 (s, 1H, -CONH), 8.27 (s, 1H, C-H triazole), 8.04 (d, $J = 8.0$ Hz, 1H, ArH), 7.98 (d, $J = 8.0$ Hz, 2H, ArH), 7.87 (d, $J = 8.0$ Hz, 1H, ArH), 7.69–7.65 (m, 2H, ArH), 7.62–7.53 (m, 3H, ArH), 7.44 (d, $J = 8.0$ Hz, 1H, ArH), 7.37–7.33 (m, 2H, ArH), 5.71 (s, 2H, -NCH₂), 4.71 (s, 2H, -SCH₂). ¹³C NMR (100 MHz, DMSO) δ 166.19 (C=O), 163.96, 151.82, 143.15 (C₄ triazole), 141.73, 139.87, 134.75, 134.23, 129.60, 128.71, 128.53, 128.34, 126.76, 126.53, 126.43, 125.99, 125.12, 124.85, 124.65 (C₅ triazole), 124.26, 123.74, 118.86, 110.73, 52.94 (-SCH₂), 26.98 (-NCH₂); HRMS (m/z) calculated for C₂₄H₁₈ClN₅O₂S [M+H]⁺: 476.0870, [M+3]⁺: 478.0840. Found: 476.0934, [M+3]⁺: 478.0898.

2.2i 4-((4-((benzo[d]oxazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(4-

bromophenyl)benzamide (**7i**): Appearance: White solid; yield: 86%; M.p.: 152–156 °C; FTIR (KBr): $\nu_{\max} = 3304$ (N–H str.), 3120 (C–H str., triazole ring), 2945 (C–H str., aliphatic), 1651 (C=O sym. str., amide), 1527, 1452 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6) δ 10.36 (s, 1H, -CONH), 8.25 (s, 1H, C-H triazole), 7.90 (d, $J = 8.0$ Hz, 2H, ArH), 7.755 (d, $J = 12.0$ Hz, 2H, ArH), 7.68–7.64 (m, 2H, ArH), 7.535 (d, $J = 12.0$ Hz, 2H, ArH), 7.40 (d, $J = 8.0$ Hz, 2H, ArH), 7.37–7.31 (m, 2H, ArH), 5.68 (s, 2H, -NCH₂), 4.69 (s, 2H, -SCH₂); ¹³C NMR (100 MHz, DMSO) δ 165.66 (C=O), 163.94, 151.81, 143.14 (C₄ triazole), 141.71, 139.95, 138.96, 134.93, 131.89, 128.60, 128.27, 125.11, 124.84, 124.63 (C₅ triazole), 122.67, 118.85, 115.83, 110.73, 52.88 (-SCH₂), 26.96 (-NCH₂); HRMS (m/z) calculated for C₂₄H₁₈BrN₅O₂S [M+H]⁺: 520.0365, [M+3]⁺: 522.0344. Found [M+H]⁺: 520.0407, [M+3]⁺: 522.0405.

2.2j 4-((4-((benzo[d]oxazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(naphthalen-1-

yl)benzamide (**7j**): Appearance: White solid; yield: 76%; M.p.: 152–156 °C; FTIR (KBr): $\nu_{\max} = 3296$ (N–H str.), 3113 (C–H str., triazole ring), 2984 (C–H str., aliphatic), 1654 (C=O sym. str., amide), 1539, 1450 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6) δ 10.36 (s, 1H, -CONH), 8.25 (s, 1H, C-H triazole), 7.90 (d, $J = 8.0$ Hz, 2H, ArH), 7.81 (d, $J = 8.0$ Hz, 2H, ArH), 7.67–7.64 (m, 2H, ArH), 7.44–7.38 (m, 4H, ArH), 7.37–7.20 (m, 5H, ArH), 5.68 (s, 2H, -NCH₂), 4.69 (s, 2H, -SCH₂). ¹³C NMR (100 MHz, DMSO) δ 165.66 (C=O), 163.94, 151.81, 143.14 (C₄ triazole), 141.71, 139.94, 138.54, 134.94, 128.98, 128.60, 128.28, 125.12, 124.85, 124.63 (C₅ triazole), 122.30, 118.85, 110.73, 52.88 (-SCH₂), 26.96 (-NCH₂); HRMS (m/z) calculated for C₂₈H₂₁N₅O₂S [M+H]⁺: 492.1450. Found: 492.1486.

2.2k 4-((4-((benzo[d]thiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-phenylbenzamide

(**7k**): Appearance: White solid; yield: 75%; M.p.: 152–156 °C; FTIR (KBr): $\nu_{\max} = 3363$ (N–H str.), 3140

(C–H str., triazole ring), 3062 (C–H str., aliphatic), 1653 (C=O sym. str., amide), 1506, 1440 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6) δ 10.23 (s, 1H, -CONH), 8.24 (s, 1H, C-H triazole), 8.02 (d, $J = 8.0$ Hz, 1H, ArH), 7.91 (d, $J = 8.0$ Hz, 2H, ArH), 7.76 (d, $J = 8.0$ Hz, 1H, ArH), 7.48 (t, $J = 8.0$, 1H, ArH), 7.41–7.08 (m, 8H, ArH), 5.68 (s, 2H, -NCH₂), 4.71 (s, 2H, -SCH₂); ¹³C NMR (100 MHz, DMSO) δ 165.54 (C=O), 143.09 (C₄ triazole), 135.21, 129.05, 128.56, 128.22, 126.84, 125.03, 124.70 (C₅ triazole), 122.29, 121.75, 120.81, 113.73, 52.88 (-SCH₂), 26.90 (-NCH₂); HRMS (m/z) calculated for C₂₄H₁₉N₅OS₂ [M+H]⁺: 458.1065. Found: 458.1098.

2.2l 4-((4-((benzo[d]thiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(o-tolyl)benzamide

(**7l**): Appearance: White solid; yield: 82%; M.p.: 152–156 °C; FTIR (KBr): $\nu_{\max} = 3361$ (N–H str.), 3109 (C–H str., triazole ring), 2951 (C–H str., aliphatic), 1643 (C=O sym. str., amide), 1517, 1423 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6) δ 9.85 (s, 1H, -CONH), 9.18 (s, 1H, C-H triazole), 8.47 (d, $J = 8.0$ Hz, 1H, ArH), 8.39 (d, $J = 8.0$ Hz, 1H, ArH), 8.15 (d, $J = 8.0$ Hz, 1H, ArH), 8.08–8.01 (m, 2H, ArH), 7.62–7.45 (m, 5H, ArH), 7.42–7.34 (t, $J = 8.0$ Hz, 2H, ArH), 5.67 (s, 2H, -NCH₂), 4.72 (s, 2H, -SCH₂), 2.67 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 165.36 (C=O), 151.85, 143.21 (C₄ triazole), 141.75, 130.85, 130.85, 128.60, 128.39, 127.07, 126.55, 125.20, 124.93, 124.73 (C₅ triazole), 118.91, 110.82, 52.93 (-SCH₂), 26.96 (-NCH₂), 18.40; HRMS (m/z) calculated for C₂₅H₂₁N₅OS₂ [M+H]⁺: 472.1221. Found: 472.1271.

2.2m 4-((4-((benzo[d]thiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(m-tolyl)benzamide

(**7m**): Appearance: White solid; yield: 79%; M.p.: 152–156 °C; FTIR (KBr): $\nu_{\max} = 3361$ (N–H str.), 3124 (C–H str., triazole ring), 2942 (C–H str., aliphatic), 1645 (C=O sym. str., amide), 1521, 1423 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6) δ 9.83 (s, 1H, -CONH), 8.22 (s, 1H, C-H triazole), 7.88 (d, $J = 8.0$ Hz, 2H), 7.62 (d, $J = 8.0$ Hz, 2H, ArH), 7.36 (d, $J = 8.0$ Hz, 2H, ArH), 7.32–7.26 (m, 3H, ArH), 7.23 (d, $J = 8.0$ Hz, 1H, ArH), 7.19–7.12 (m, 2H, ArH), 5.63 (s, 2H, -NCH₂), 4.65 (s, 2H, -SCH₂), 2.17 (s, 3H, -CH₃). ¹³C NMR (100 MHz, DMSO) δ 165.36 (C=O), 151.85, 143.21 (C₄ triazole), 141.75, 130.85, 130.85, 128.60, 128.39, 127.07, 126.55, 125.20, 124.93, 124.73 (C₅ triazole), 118.91, 110.82, 52.93 (-SCH₂), 26.96 (-NCH₂), 18.40; HRMS (m/z) calculated for C₂₅H₂₁N₅OS₂ [M+H]⁺: 472.1221. Found: 472.1271.

2.2n 4-((4-((benzo[d]thiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(p-tolyl)benzamide

(**7n**): Appearance: Brown solid; yield: 80%; M.p.: 152–156 °C; FTIR (KBr): $\nu_{\max} = 3361$ (N–H str.), 3120 (C–H str., triazole ring), 2956 (C–H str., aliphatic), 1651 (C=O sym. str., amide), 1508, 1408 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6) δ 10.14 (s, 1H,

-CONH), 8.22 (s, 1H, C-H triazole), 7.85 (d, $J = 8.0$ Hz, 2H, ArH), 7.64–7.58 (m, 3H, ArH), 7.35 (d, $J = 8.0$ Hz, 2H, ArH), 7.30 (t, $J = 4.0$ Hz, 2H, ArH), 7.20 (s, 1H, ArH), 7.11 (d, $J = 8.0$ Hz, 2H), 5.63 (s, 2H, -NCH₂), 4.65 (s, 2H, -SCH₂), 2.23 (s, 3H, -CH₃). ¹³C NMR (100 MHz, DMSO) δ 165.41 (C=O), 164.03, 151.85, 143.20 (C₄ triazole), 141.74, 139.76, 137.07, 135.32, 133.18, 129.53, 128.58, 128.30, 125.20, 124.92, 124.73 (C₅ triazole), 120.85, 118.91, 110.82, 52.92 (-SCH₂), 26.96 (-NCH₂), 21.03; HRMS (m/z) calculated for C₂₅H₂₁N₅OS₂ [M+H]⁺: 472. 1221. Found: 472.1271.

2.2o 4-((4-((benzo[d]thiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(4-methoxyphenyl)benzamide (**7o**): Appearance: Brown solid; yield: 83%; M.p.: 152–156 °C; FTIR (KBr): ν_{\max} = 3361 (N–H str.), 3109 (C–H str., triazole ring), 2951 (C–H str., aliphatic), 1643 (C=O sym. str., amide), 1517, 1423 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.07 (s, 1H, -CONH), 8.20 (s, 1H, C-H triazole), 7.98 (d, $J = 8.0$ Hz, 1H, ArH), 7.84 (m, 3H, ArH), 7.61 (d, $J = 8.0$ Hz, 2H, ArH), 7.44 (t, $J = 8.0$ Hz, 2H, ArH), 7.36–7.32 (m, 2H, ArH), 6.88 (d, $J = 8.0$ Hz, 2H, ArH), 5.63 (s, 2H, -NCH₂), 4.67 (s, 2H, -SCH₂), 3.70 (s, 3H, -OCH₃). ¹³C NMR (100 MHz, DMSO) δ 166.33 (C=O), 153.23, 144.97 (C₄ triazole), 139.71, 135.24, 132.79, 128.50, 128.28, 126.93, 125.11 (C₅ triazole), 122.42, 121.80, 114.26, 55.68, 52.91 (-SCH₂), 28.08 (-NCH₂); HRMS (m/z) calculated for C₂₅H₂₁N₅OS₂ [M+H]⁺: 488.1170. Found: 488.1203.

2.2p 4-((4-((benzo[d]thiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(4-nitrophenyl)benzamide (**7p**): Appearance: White solid; yield: 72%; M.p.: 152–156 °C; FTIR (KBr): ν_{\max} = 3356 (N–H str.), 3112 (C–H str., triazole ring), 2953 (C–H str., aliphatic), 1658 (C=O sym. str., amide), 1506, 1423 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.75 (s, 1H, -CONH), 8.26 – 8.20 (m, 3H, C-H triazole, ArH), 7.99 (t, $J = 8.0$ Hz, 3H, ArH), 7.86 (t, $J = 8.0$ Hz, 3H, ArH), 7.46 – 7.30 (m, 4H, ArH), 5.65 (s, 2H, -NCH₂), 4.67 (s, 2H, -SCH₂). ¹³C NMR (100 MHz, DMSO) δ 166.30 (C=O), 164.16, 151.56, 143.52 (C₄ triazole), 128.91, 128.41, 126.92, 125.37, 125.11, 124.84 (C₅ triazole), 122.38, 121.80, 120.34, 52.88 (-SCH₂), 27.93 (-NCH₂); HRMS (m/z) calculated for C₂₄H₁₈N₆O₃S₂ [M+H]⁺: 503. 0915. Found: 503.0951.

2.2q 4-((4-((benzo[d]thiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(4-fluorophenyl)benzamide (**7q**): Appearance: White solid; yield: 81%; M.p.: 152–156 °C; FTIR (KBr): ν_{\max} = 3361 (N–H str.), 3107 (C–H str., triazole ring), 3062 (C–H str., aliphatic), 1651 (C=O sym. str., amide), 150, 1458 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.25 (s, 1H, -CONH), 8.23 (s, 1H, C-H

triazole), 8.02 (d, $J = 8.0$ Hz, 1H, ArH), 7.89 (d, $J = 8.0$ Hz, 3H, ArH), 7.79–7.73 (m, 2H, ArH), 7.51–7.46 (m, 1H, ArH), 7.42–7.35 (m, 3H, ArH), 7.23–7.16 (m, 2H, ArH), 5.68 (s, 2H, -NCH₂), 4.71 (s, 2H, -SCH₂). ¹³C NMR (100 MHz, DMSO) δ 165.00 (C=O), 163.33, 152.16, 145.86 (C₄ triazole), 141.25, 139.92, 137.23, 135.10, 128.51, 128.25, 126.84, 125.03, 124.68 (C₅ triazole), 123.32, 122.65, 122.58, 122.28, 121.74, 116.21, 115.76, 115.54, 52.92 (-SCH₂), 27.96 (-NCH₂); HRMS (m/z) calculated for C₂₄H₁₈N₅OS₂ [M+H]⁺: 476. 0970. Found: 476.1016.

2.2r 4-((4-((benzo[d]thiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(4-chlorophenyl)benzamide (**7r**): Appearance: White solid; yield: 78%; M.p.: 152–156 °C; FTIR (KBr): ν_{\max} = 3284 (N–H str.), 3115 (C–H str., triazole ring), 2939 (C–H str., aliphatic), 1656 (C=O sym. str., amide), 1539, 1419 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.35 (s, 1H, -CONH), 8.23 (s, 1H, C-H triazole), 8.02 (d, $J = 8.0$ Hz, 1H, ArH), 7.98–7.87 (m, 3H, ArH), 7.81 (d, $J = 8.0$ Hz, 2H, ArH), 7.56–7.44 (m, 1H, ArH), 7.45–7.35 (m, 5H, ArH), 5.68 (s, 2H, -NCH₂), 4.71 (s, 2H, -SCH₂). ¹³C NMR (100 MHz, DMSO) δ 166.11 (C=O), 165.65, 153.06, 143.23 (C₄ triazole), 139.97, 138.54, 135.20, 134.93, 128.98, 128.59, 128.25, 127.77, 126.84, 125.03, 124.70 (C₅ triazole), 122.29, 121.74, 52.87, 40.67, 40.46, 40.25, 40.04, 39.83, 39.63, 39.42, 27.96; HRMS (m/z) calculated for C₂₄H₁₈ClN₅OS₂ [M+H]⁺: 492.0641, [M+3]⁺: 494.0612. Found: 492.0707, [M+3]⁺: 494.0676.

2.2s 4-((4-((benzo[d]thiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(4-bromophenyl)benzamide (**7s**): Appearance: White solid; yield: 73%; M.p.: 152–156 °C; FTIR (KBr): ν_{\max} = 3284 (N–H str.), 3111 (C–H str., triazole ring), 2946 (C–H str., aliphatic), 1654 (C=O sym. str., amide), 1527, 1425 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.33 (s, 1H, -CONH), 8.23 (s, 1H, C-H triazole), 8.02 (d, $J = 8.0$ Hz, 1H), 7.89 (d, $J = 8.0$ Hz, 3H), 7.75 (d, $J = 8.0$ Hz, 2H), 7.54 (d, $J = 8.0$ Hz, 2H), 7.48 (t, $J = 8.0$ Hz, 1H), 7.42–7.34 (m, 3H), 5.68 (s, 2H, -NCH₂), 4.71 (s, 2H, -SCH₂). ¹³C NMR (100 MHz, DMSO) δ 165.68 (C=O), 153.06, 143.25 (C₄ triazole), 140.00, 138.96, 135.21, 131.92, 128.59, 128.27, 126.85, 125.04, 124.71 (C₅ triazole), 122.65, 122.30, 121.75, 52.87 (-SCH₂), 27.95 (-NCH₂); HRMS (m/z) calculated for C₂₄H₁₈BrN₅OS₂ [M+H]⁺: 536.0136, [M+3]⁺: 538.0116. Found: [M+H]⁺: 536.0183, [M+3]⁺: 538.0185.

2.2t 4-((4-((benzo[d]thiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(naphthalen-1-yl)benzamide (**7t**): Appearance: Brown solid; yield: 85%; M.p.: 152–156 °C; FTIR (KBr): ν_{\max} = 3305 (N–H str.), 3115 (C–H str., triazole ring), 2954 (C–H str., aliphatic), 1647 (C=O sym. str., amide), 1529, 1429 (C=C str., aromatic ring), cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆)

δ 10.40 (s, 1H, -CONH), 8.26 (s, 1H, C-H triazole), 8.06–8.01 (m, 2H, ArH), 7.98 (t, $J = 8.0$ Hz, 2H, ArH), 7.89 (dd, $J = 16.0, 8.0$ Hz, 2H, ArH), 7.63–7.53 (m, 5H, ArH), 7.49 (t, $J = 8.0$ Hz, 1H, ArH), 7.44 (d, $J = 8.0$ Hz, 2H, ArH), 7.38 (t, $J = 16.0$ Hz, 1H, ArH), 5.71 (s, 2H, -NCH₂), 4.73 (s, 2H, -SCH₂). ¹³C NMR (100 MHz, DMSO) δ 166.19 (C=O), 166.12, 153.07, 143.25 (C₄ triazole), 139.91, 135.22, 134.73, 134.23, 129.60, 128.70, 128.53, 128.32, 126.85, 126.76, 126.53, 126.43, 126.00, 125.04, 124.73 (C₅ triazole), 124.27, 123.74, 122.29, 121.76, 52.93 (-SCH₂), 27.98 (-NCH₂); HRMS (m/z) calculated for C₂₈H₂₁N₅OS₂ [M+H]⁺: 508.1221. Found: 508.1253.

2.3 General procedure for *in vitro* antibacterial evaluation

All the newly synthesized triazole derivatives were screened for *in vitro* antibacterial activity against *S. aureus* (MTCC 7443), *B. subtilis* (MTCC 441) as Gram-positive bacterial strains and *E. coli* (MTCC 1231), *K. pneumoniae* (NCDC 138) as Gram-negative bacterial strains, by standard serial dilution technique.³⁸ Stock solution of 200 μ g/mL concentration was prepared by dissolving 2.0 mg of the synthesized compound in 10 mL of DMSO. The fresh nutrient broth was used as a culture media for bacterial strains. Firstly, 1 mL of nutrient broth was taken in each test tube. Then, 1 mL of stock solution was added in the first test tube to get the solution of 100 μ g/mL concentration. From this solution, concentrations of 50–6.25 μ g/mL were obtained in other test tubes through serial dilution technique. Then, 0.1 mL of respective microorganism in sterile saline was injected in each test tube and then incubated at 37 °C for 24 h. Results were recorded visually in terms of Minimum Inhibitory Concentration (MIC) in μ mol/mL.

3. Results and Discussion

3.1 Chemistry

The synthetic pathways adopted for the synthesis of benzothiazole and benzoxazole containing triazoles (**7a-7t**) have been presented in Scheme 1. The terminal alkynes *viz.*, 2-(prop-2-yn-1-ylthio)benzoxazole (**3a**)/2-(prop-2-yn-1-ylthio)benzothiazole (**3b**) were obtained from the propargylation of 2-mercaptobenzoxazole (**1a**)/2-mercaptobenzothiazole (**1b**) in DMF with propargyl bromide (**2**) in the presence of potassium carbonate.

4-(Bromomethyl)-N-arylbenzamide (**6a-6j**) were synthesized by reaction of 4-(bromomethyl)benzoyl-bromide (**4**) and aromatic amines (**5a-5j**) by using potassium carbonate.

Finally, 4-(bromomethyl)-N-arylbenzamide derivatives (**6a-6j**) and 2-(prop-2-yn-1-ylthio)benzoxazole

(**3a**)/2-(prop-2-yn-1-ylthio)benzothiazole (**3b**) were dissolved in DMF followed by addition of aqueous sodium azide, a catalytic amount of copper sulphate pentahydrate, sodium ascorbate and continued stirring for 6–10 h at 25–40 °C to obtain targeted 1,4-disubstituted 1,2,3-triazoles (**7a-7t**).


The structures of synthesized triazoles (**7a-7t**) were confirmed by FTIR, ¹H NMR, ¹³C NMR spectroscopy and HRMS. In FTIR spectra of all the compounds characteristic absorption band due to C–H stretching of triazole ring observed at 3199–3107 cm⁻¹, N–H stretching of amide linkages at 3365–3257 cm⁻¹ and 1660–1643 cm⁻¹ were due to C=O stretching of amide bonds. The ¹H NMR spectra of all the compounds exhibited characteristic singlet due to N–H proton in the range of δ 10.07–10.77. A singlet in a range of δ 8.22–8.29 was assigned to triazolyl proton. Two singlets in the range of δ 4.65–4.71 and δ 5.63–5.71 in the ¹H-NMR spectra assigned to -SCH₂ and -NCH₂, respectively.

In ¹³C-NMR spectral data, a characteristic signal of carbon of C=O of amide appeared in the range of δ 166.14–165.31. C–4 and C–5 signals corresponding to triazole ring appeared at δ 143.00–143.30 and δ 124.62–124.93, respectively. A signal in the range of δ 26.90–27.94 appeared due to carbon attached to sulphur and a signal in the range of δ 52.91–52.98 due to methylene carbon attached to nitrogen of triazole. The final confirmation was made by the HRMS analysis which showed the presence of [M+H]⁺ ion peaks.

3.2 Antibacterial activity

All the synthesized 1,2,3-triazoles were screened for antibacterial activities of against two Gram-positive bacteria *S. aureus*, *B. subtilis*, two Gram-negative bacteria *E. coli* and *K. pneumoniae* via serial dilution method. Ciprofloxacin was used as a standard against both Gram-positive and Gram-negative bacteria. The MIC values of synthesized compounds are presented in Table 1.

It has been observed that in most of the cases the presence of any substituent on benzene ring led to increased activity towards all the tested bacterial strain. Further, the presence of electron-withdrawing group showed an advantage over an electron-donating group on the benzene ring. The compounds **7f**, **7p** with a nitro group showed enhanced activity than its unsubstituted or alkyl-substituted analogs. 1,2,3-triazoles containing methyl group at *meta* position (**7c**, **7m**), showed better activity than its *ortho* or *para*



Compounds	X	R	Reaction time (h)	Yield (%)
7a	O	C ₆ H ₅	8	79
7b	O	2-CH ₃ C ₆ H ₄	10	81
7c	O	3-CH ₃ C ₆ H ₄	9	85
7d	O	4-CH ₃ C ₆ H ₄	7	82
7e	O	4-OCH ₃ C ₆ H ₄	9	83
7f	O	4-NO ₂ C ₆ H ₄	6	78
7g	O	4-FC ₆ H ₄	9	81
7h	O	4-ClC ₆ H ₄	10	77
7i	O	4-BrC ₆ H ₄	10	86
7j	O	α-naphthyl	10	76
7k	S	C ₆ H ₅	6	75
7l	S	2-CH ₃ C ₆ H ₄	10	82
7m	S	3-CH ₃ C ₆ H ₄	9	79
7n	S	4-CH ₃ C ₆ H ₄	7	80
7o	S	4-OCH ₃ C ₆ H ₄	8	83
7p	S	4-NO ₂ C ₆ H ₄	6	72
7q	S	4-FC ₆ H ₄	8	81
7r	S	4-ClC ₆ H ₄	9	78
7s	S	4-BrC ₆ H ₄	9	73
7t	S	α-naphthyl	10	85

Scheme 1. Synthesis of benzothiazole and benzoxazole linked 1,4-disubstituted 1,2,3-triazoles.

Table 1. *In vitro* antibacterial activity of synthesized triazoles (**7a-7t**) (MIC in $\mu\text{mol/mL}$).

Compounds	Gram positive bacteria		Gram negative bacteria	
	<i>Staphylococcus aureus</i> (MTCC 7443)	<i>Bacillus subtilis</i> (MTCC 441)	<i>Klebsiella pneumoniae</i> (NCDC 138)	<i>Escherichia coli</i> (MTCC1231)
7a	0.113	0.056	0.056	0.113
7b	0.219	0.109	0.054	0.109
7c	0.054	0.054	0.054	0.054
7d	0.054	0.054	0.109	0.109
7e	0.212	0.106	0.212	0.106
7f	0.051	0.051	0.051	0.102
7g	0.108	0.054	0.054	0.108
7h	0.210	0.105	0.052	0.105
7i	0.024	0.024	0.024	0.048
7j	0.102	0.025	0.025	0.102
7k	0.081	0.054	0.054	0.054
7l	0.212	0.212	0.053	0.053
7m	0.053	0.053	0.053	0.053
7n	0.102	0.053	0.053	0.212
7o	0.205	0.051	0.051	0.102
7p	0.098	0.049	0.049	0.049
7q	0.053	0.105	0.105	0.105
7r	0.101	0.050	0.050	0.101
7s	0.023	0.023	0.023	0.046
7t	0.049	0.049	0.024	0.024
Ciprofloxacin	0.019	0.019	0.019	0.019

counterparts. Compounds **7i**, **7s** containing bromo group on benzene ring exhibited better activity in comparison with fluoro and chloro substituents. Compounds **7j** and **7t** with naphthyl ring displayed potential activity against all the tested bacterial strains. All the triazole derivatives containing benzothiazole ring exhibited better efficacy as compared to the benzoxazole ring.

4. Conclusions

In the present case, we have synthesized a new promising class of benzothiazole-triazole and benzoxazole-triazole hybrids (**7a-7t**) through click reaction in good yields by reacting 2-(prop-2-yn-1-ylthio)benzoxazole (**3a**)/2-(prop-2-yn-1-ylthio)benzothiazole (**3b**) with appropriate 4-(bromomethyl)-N-arylbenzamides (**6a-6j**) and sodium azide. The synthesized disubstituted-1,2,3-triazoles reflected encouraging antibacterial activity. However, compound **7s** exhibited promising antibacterial activity comparable with standard drug Ciprofloxacin.

Supplementary Information (SI)

^1H NMR, ^{13}C NMR and HRMS spectra of all the synthesized compounds are available at www.ias.ac.in/chemsci.

Acknowledgement

Authors are highly thankful to the Council of Scientific and Industrial Research (CSIR), New Delhi, India.

Compliance with ethical standards

Conflicts of interest No potential conflict of interest was reported by the authors.

References

- Singh G, Chowdhary K, Satija P, Singh A, Singh B, Singh K, Espinosa C B, Esteban M A, Sehgal R and Verma V 2018 Synthesis and immobilization of benzothiazole-appended triazole-silane: Biological evaluation and molecular docking approach *Chem. Select* **3** 1609
- Kumbhare R M, Dadmal T, Kosurkar U, Sridhar V and Rao J V 2012 Synthesis and cytotoxic evaluation of thiourea and N-bis-benzothiazole derivatives: A novel class of cytotoxic agents *Bioorg. Med. Chem. Lett.* **22** 453
- Aouad M R, Soliman M A, Alharbi M O, Bardaweel S K, Sahu P K, Ali A A, Messali M, Rezki N and Soud Y A A 2018 Design, synthesis and anticancer screening of novel benzothiazole-piperazine-1,2,3-triazole hybrids *Molecules* **23** 2788

4. Santhoshi A and Alam H 2014 Synthesis of thio-pyrimidine, benzoxazole, benzothiazole and triazole analogues from Baylis-Hillman Bromides as potent cyclooxygenase-2 inhibitors *J. Chem. Pharm. Sci.* 2014 Special Issue
5. Chandramouli, Shivanand M R, Nayanbhai T B, Bheemachari and Udipi R H 2012 Synthesis and biological screening of certain new triazole schiff bases and their derivatives bearing substituted benzothiazole moiety *J. Chem. Pharm. Res.* **4** 1151
6. Faraji L, Shahkarami S, Nadri H, Moradi A, Saeedi M, Foroumadi A, Ramazani A, Haririan I, Ganjali M R, Shafiee A and Khoobi M 2017 Synthesis of novel benzimidazole and benzothiazole derivatives bearing a 1,2,3-triazole ring system and their acetylcholinesterase inhibitory activity *J. Chem. Res.* **41** 30
7. Raju K S, Reddy S A, Sabitha G, Krishna V S, Sriram D, Reddy K B and Sagurthi S R 2019 Synthesis and biological evaluation of 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives as novel anti-tubercular agents *Bioorg. Med. Chem. Lett.* **29** 284
8. Li H, Wang H, Wang Z, Yan H, Zhang M, Liu Y and Cheng M 2018 Synthesis, antitumor activity evaluation and mechanistic study of novel hederacolchiside A₁ derivatives bearing an aryl triazole moiety *Bioorg. Med. Chem.* **26** 4025
9. Gilandoust M, Harsha K B, Mohan C D, Raquib A R, Rangappa S, Pandey V, Lobie P E, Basappa and Rangappa K S 2018 Synthesis, characterization and cytotoxicity studies of 1,2,3-triazoles and 1, 2,4-triazolo [1,5-a] pyrimidines in human breast cancer cells *Bioorg. Med. Chem. Lett.* **28** 2314
10. Shankaraiah N, Kumar N P, Tokala R, Gayatri B S, Talla V and Santos L S 2019 Synthesis of new 1,2,3-triazolo-naphthalimide/phthalimide conjugates via 'click' reaction: DNA intercalation and cytotoxic studies *J. Braz. Chem. Soc.* **30** 454
11. Lu G Q, Li X Y, Mohamed O K, Wang D and Meng F H 2019 Design, synthesis and biological evaluation of novel uracil derivatives bearing 1, 2, 3-triazole moiety as thymidylate synthase (TS) inhibitors and as potential antitumor drugs *Eur. J. Med. Chem.* **171** 282
12. Pasupuleti B G, Khongsti K, Das B and Bez G 2020 1, 2, 3-Triazole tethered 1, 2, 4-trioxanes: Studies on their synthesis and effect on osteopontin expression in MDA-MB-435 breast cancer cells *Eur. J. Med. Chem.* **186** 111908
13. Shinoda K, Kanai M and Sohma Y 2020 Design, synthesis, and properties of a chemically-tethered amyloid- β segment trimer resistant to inter-trimer mis-aggregation *J. Org. Chem.* **85** 1635
14. Zimmermann L A, Moraes M H, Rosa R, Melo E B, Paula F R, Schenkela E P Steindel, M and Bernardes L S C 2018 Synthesis and SAR of new isoxazole-triazole bis-heterocyclic compounds as analogues of natural lignans with antiparasitic activity *Bioorg. Med. Chem.* **26** 4850
15. Tan W, Li Q, Dong F, Zhanga J, Luana F, Wei L, Chena Y and Guo Z 2018 Novel cationic chitosan derivative bearing 1,2,3-triazolium and pyridinium: Synthesis, characterization, and antifungal property *Carbohydr. Polym.* **182** 180
16. Govindaiah S, Sreenivasa S, Ramakrishna R A, Rao T M C and Nagabhushana H 2018 Regioselective synthesis, antibacterial, molecular docking and fingerprint applications of 1-benzhydrylpiperazine derivatized 1,4-disubstituted 1,2,3-triazoles *Chem. Select* **3** 8111
17. Zhou J, Stapleton P, Haider S and Healy J 2018 Boronic acid inhibitors of the class A β -lactamase KPC-2 *Bioorg. Med. Chem.* **26** 2921
18. Abbaspour S, Keivanloo A, Bakherad M and Sepehri S 2019 Salophen copper(II) complex-assisted click reactions for fast synthesis of 1,2,3-triazoles based on naphthalene-1,4-dione scaffold, antibacterial evaluation, and molecular docking studies *Chem. Biodivers.* **16** e1800410
19. Kaushik C P, Luxmi R, Kumar A, Kumar K and Pahwa A 2019 Antibacterial evaluation and QSAR studies of 1,2,3-triazole bridged with amide functionality *Indian J. Chem.* **58B** 88
20. Torres L M F C, Almeida M T, Santos T L, Marinho L E S, Mesquita J P, Silva L M, Santos W T P, Martins H R, Kato K C, Alves E S F, Liao L M, Magalhaes M T Q, Mendonça F G, Pereira F V, Resende J M, Bemquerer M P, Rodrigues M A and Verly R M 2019 Antimicrobial alumina nanobiostructures of disulfide- and triazole-linked peptides: Synthesis, characterization, membrane interactions and biological activity *Colloids Surf. B* **177** 94
21. Bommagani M B, Mokenapelli S, Yerrabelli J R, Boda S K and Chitneni P R 2020 Novel 4-(1H-1, 2, 3-triazol-4-yl) methoxy) cinnolines as potent antibacterial agents: Synthesis and molecular docking study *Synth. Commun.* **50** 1016
22. Deswal S, Naveen, Tittal R K, Vikas D G, Lal K and Kumar A 2020 5-Fluoro-1H-indole-2, 3-dione-triazoles-synthesis, biological activity, molecular docking, and DFT study *J. Mol. Struct.* **1209** 127982
23. Gontijo V S, Espuri P F, Alves R B, Camargos L F, Santos F V, Alves W, Marques M and Freitas R 2015 Leishmanicidal, antiproteolytic, and mutagenic evaluation of alkyltriazoles and alkylphosphocholines *Eur. J. Med. Chem.* **101** 24
24. Bonache M A, Fernandez S M, Miguel M, Munoz B S and Muniz R G 2018 Small library of triazolyl polyphenols correlating antioxidant activity and stability with number and position of hydroxyl groups *ACS Comb. Sci.* **20** 694
25. Kaushik C P and Luxmi R 2020 Synthesis, antibacterial, and antioxidant activities of naphthyl-linked disubstituted 1,2,3-triazoles *J. Het. Chem.* **57** 2400
26. Kumar A K, Sunitha V, Shankar B, Ramesh M, Krishna T M and Jalapathi P 2016 Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel 1,2,3-Triazole Derivatives as Potent Anti-Inflammatory Agents *Russ. J. Gen. Chem.* **86** 1154
27. Maurent K, Bacque C V, Baltas M, Salvayre A N, Auge N and Belval F B 2018 Synthesis and biological evaluation of diarylheptanoids as potential antioxidant and anti-inflammatory agents *Eur. J. Med. Chem.* **144** 289
28. Litchfield M, Wuest M, Glubrecht D and Wues F 2020 Radiosynthesis and Biological Evaluation of [¹⁸F] Triacoxib: A New Radiotracer for PET Imaging of COX-2 *Mol. Pharm.* **17** 251

29. Sahu A, Das D, Sahu P, Mishra S, Sakthivel A, Gajbhiye A and Agrawal R 2020 Bioisosteric replacement of amide group with 1,2,3-triazoles in acetaminophen addresses reactive oxygen species-mediated hepatotoxic insult in Wistar albino rats *Chem. Res. Toxicol.* **33** 522
30. Devender N, Gunjan S, Tripathi R and Tripathi R P 2017 Synthesis and antiplasmodial activity of novel indoleamide derivatives bearing sulfonamide and triazole pharmacophores *Eur. J. Med. Chem.* **131** 171
31. Wang G, Peng Z, Wang J, Li X and Li J 2017 Synthesis, in vitro evaluation and molecular docking studies of novel triazine-triazole derivatives as potent α -glycosidase inhibitors *Eur. J. Med. Chem.* **125** 423
32. Tian Y, Liu Z, Liu J, Huang B, Kang D, Zhang H, Clercq E D, Daelemans D, Pannecouque C, Lee K H, Chen C H, Zhan P and Liu X 2018 Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wildtype and E138K mutant virus *Eur. J. Med. Chem.* **151** 339
33. Tantray M A, Khan I, Hamid H, Alam M S, Dhulap A and Kalam A 2016 Synthesis of benzimidazole-based 1,3,4-oxadiazole-1,2,3-triazole conjugates as glycogen synthase kinase-3 β inhibitors with antidepressant activity in *in vivo* models *RSC Adv.* **6** 43345
34. Bagheri S M, Khoobi M, Nadri H, Moradi A, Emami S, Baleh L J, Jafarpour F, Moghadam F H, Foroumadi A and Shafie A 2015 Synthesis and anticholinergic activity of 4-hydroxycoumarin derivatives containing substituted benzyl-1,2,3-triazole moiety *Chem. Biol. Drug Des.* **86** 1215
35. Fatih C, Yasemin U, Burak B, Arzu O and Kemal S 2018 Synthesis, characterization and biological activities of new symmetric bis-1,2,3-triazoles with click chemistry *Med. Chem.* **14** 230
36. Shafi S, Alam M M, Mulakayala N, Mulakayala C, Vanaja G, Kalle A M, Pallu R and Alam M S 2012 Synthesis of novel 2-mercapto benzothiazole and 1,2,3-triazole based bis-heterocycles: Their anti-inflammatory and anti-nociceptive activities *Eur. J. Med. Chem.* **49** 324
37. Haider S, Alam M S, Hamid H, Shafi S, Dhulap A, Hussain F, Alam P, Umar S, Pasha M A Q, Bano S, Nazreen S, Ali Y and Kharbanda C 2014 Synthesis of novel 2-mercaptobenzoxazole based 1,2,3-triazoles as inhibitors of proinflammatory cytokines and suppressors of COX-2 gene expression *Eur. J. Med. Chem.* **81** 204
38. Kaushik C P, Pahwa A, Singh D, Kumar K and Luxmi R 2019 Efficient synthesis, antitubercular and antimicrobial evaluation of 1, 4-disubstituted 1, 2, 3-triazoles with amide functionality *Montash. Chem.* **150** 1127